CLINICAL TRIALS PROFILE FOR SHR0302
✉ Email this page to a colleague
Clinical Trials for SHR0302
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02423538 ↗ | First-in-Human Single Ascending Dose of SHR0302 | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) oral doses of SHR0302 compared to placebo. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of SHR0302 after single oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined. |
NCT02665910 ↗ | Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Condition: Rheumatoid Arthritis Intervention: Drug: SHR0302; Drug: SHR0302 placebo comparator Phase: Phase 1 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized |
NCT02892370 ↗ | Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | The purpose of this open-label, randomized, two-period, two-treatment (single doses of 10 mg SHR0302 fasted or fed), crossover study was to evaluate the effect of a high-fat meal on the pharmacokinetics of SHR0302 and mass balance study in 14 healthy subjects. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for SHR0302
Condition Name
Clinical Trial Locations for SHR0302
Trials by Country
Clinical Trial Progress for SHR0302
Clinical Trial Phase
Clinical Trial Sponsors for SHR0302
Sponsor Name